Erratum

Journal of the European Academy of Dermatology and VenereologyVolume 29, Issue 1 p. 193-194 ErratumFree Access Erratum This article corrects the following: The risk of deep fungal infections during biologic therapy for psoriasis N. Jourabchi, L. Adelzadeh, J.J. Wu, Volume 28Issue 10Journal of the European Academy of Dermatology and Venereology pages: 1277-1285 First Published online: June 10, 2014 First published: 22 December 2014 https://doi.org/10.1111/jdv.12837AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat The risk of deep fungal infections during biologic therapy for psoriasis; J Eur Acad Dermatol Venereol 2014. In Table 1, “Leonardi et al.56” and “*Non-viral, non-bacterial opportunistic infection, not otherwise specified.” should have been deleted. The correct Table 1 should have read: Table 1. Biologics exposure data summary Author Year Country Biologic Patients exposed to biologic Data Source Reported deep fungal infections Bagel et al.19 2012 USA, Canada Etanercept 62 RCT 0 Leonardi et al.20 2003 USA Etanercept 486 RCT 0 Tyring et al.21 2006 USA, Canada Etanercept 311 RCT 0 van de Kerkhof et al.22 2008 International Etanercept 96 RCT 0 Gottlieb et al.23 2003 USA Etanercept 57 RCT 0 Yang et al.24 2012 China Infliximab 84 RCT 0 Chaudhari et al.25 2001 USA Infliximab 22 RCT 0 Gottlieb et al.26 2004 USA Infliximab 198 RCT 0 Reich et al.27 2005 International Infliximab 301 RCT 0 Menter et al.28 2007 USA, Canada Infliximab 627 RCT 0 Torii et al.29 2010 Japan Infliximab 35 RCT 0 Leonardi et al.30 2011 USA, Canada Adalimumab 49 RCT 0 Asahina et al.31 2010 Japan Adalimumab 123 RCT 0 Gordon et al.32 2006 USA, Canada Adalimumab 97 RCT 1aa Coccidiomycosis. Saurat et al.33 2008 International Adalimumab 108 RCT 0 Menter et al.34 2008 USA, Canada Adalimumab 814 RCT 0 Leonardi et al.35 2008 USA, Canada Ustekinumab 511 RCT 0 Tsai et al.36 2011 Korea, Taiwan Ustekinumab 61 RCT 0 Igarashi et al.37 2012 Japan Ustekinumab 126 RCT 0 Krueger et al.38 2007 International Ustekinumab 256 RCT 0 Gottlieb et al.39 2012 USA, Canada Etanercept Etanercept combined with methotrexate 239 239 RCT 0 Zachariae et al.40 2008 Denmark, Finland, Norway, Sweden Etanercept with methotrexate taper Etanercept combined with continued methotrexate 28 31 RCT 0 Barker et al.41 2011 Europe Infliximab 649 RCT 0 Griffiths et al.42 2010 International Etanercept Ustekinumab 347 556 RCT 0 Reich et al.44 2013 International Infliximab 441 ET 0 Pariser et al.45 2012 International Etanercept 4410 ET 0 Papp et al.46 2012 Canada Etanercept 506 ET 0 Gordon et al.47 2012 USA, Canada Adalimumab 1159 ET 0 Garcia-Doval et al.51 2012 Spain Etanercept Adalimumab Infliximab Ustekinumab 447 343 163 101 Registry 0 Kimball et al.53 2013 USA, Canada Etanercept 2511 Registry 0 Kerdel et al.54 2013 International Adalimumab 4733 Registry 0 van Lumig et al.55 2012 Netherlands Etanercept Adalimumab Infliximab Ustekinumab 94 13 3 2 Registry 0 Kamili et al.57 2010 USA Infliximab in combination with methotrexate and prednisone 1 CR 1bb Histoplasmosis. Hoang et al.58 2007 USA Etanercept 1 CR 1cc Cryptococcus. a Coccidiomycosis. b Histoplasmosis. c Cryptococcus. CR, Case report; ET, Extension trial(s); RCT, Randomized controlled trial. Page 5, left column, 4th paragraph “Of the 11 900 patients enrolled in the international PSOriasis Longitudinal Assessment Registry (PSOLAR), from 2007 to August 23, 2012, there were 119 reported cases of non-viral, non-bacterial opportunistic infections in psoriatic patients on biologics (n = 9651) and 27 cases in patients who were not on biologic medications (n = 2249). Data is not yet available on how many of these cases of opportunistic infection are attributable to deep fungal infections. Fifty-nine of the cases occurred in patients on ustekinumab (n = 3796), 20 of the cases occurred in patients on infliximab (n = 1331) or golimumab (n = 32) and 40 cases occurred in patients on adalimumab and/or etanercept (n = 4283) or efalizumab, alefacept, or another non-sponsor biologic (n = 209).56” should have been deleted. Page 6, right column, 3rd paragraph “We also found 119 cases of non-viral, non-bacterial opportunistic infections from preliminary data of serious infections in the PSOLAR registry, although data is not yet available on how many of these cases of opportunistic infection are attributable to deep fungal infections.” should have been deleted. Reference 1Jourabchi N, Adelzadeh L, Wu JJ. The risk of deep fungal infections during biologic therapy for psoriasis, J Eur Acad Dermatol Venereol 2014; 28: 1277– 1285. Wiley Online LibraryCASPubMedWeb of Science®Google Scholar Volume29, Issue1January 2015Pages 193-194 ReferencesRelatedInformation

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.